Dr. Christopher Bartalos, MD
Claim this profileBVL Clinical Research
Studies Crohn's Disease
Studies Ulcerative Colitis
9 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Christopher Bartalos, MD is currently running
TAK-279
for Ulcerative Colitis
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Recruiting0 awards Phase 21 criteria
Vedolizumab + Adalimumab/Ustekinumab
for Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.
Recruiting3 awards Phase 410 criteria
More about Christopher Bartalos, MD
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Christopher Bartalos, MD has experience with
- Mirikizumab
- TAK-279
- Vedolizumab
- ABX464
- CDPATH™
- Tofacitinib
Breakdown of trials Christopher Bartalos, MD has run
Crohn's Disease
Ulcerative Colitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher Bartalos, MD specialize in?
Christopher Bartalos, MD focuses on Crohn's Disease and Ulcerative Colitis. In particular, much of their work with Crohn's Disease has involved treating patients, or patients who are undergoing treatment.
Is Christopher Bartalos, MD currently recruiting for clinical trials?
Yes, Christopher Bartalos, MD is currently recruiting for 4 clinical trials in Leawood Kansas. If you're interested in participating, you should apply.
Are there any treatments that Christopher Bartalos, MD has studied deeply?
Yes, Christopher Bartalos, MD has studied treatments such as Mirikizumab, TAK-279, Vedolizumab.
What is the best way to schedule an appointment with Christopher Bartalos, MD?
Apply for one of the trials that Christopher Bartalos, MD is conducting.
What is the office address of Christopher Bartalos, MD?
The office of Christopher Bartalos, MD is located at: BVL Clinical Research, Leawood, Kansas 66211 United States. This is the address for their practice at the BVL Clinical Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.